Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of mRNA-0184 in Healthy Participants
NCT06243770Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mRNA-0184 in heart failure (HF) (6 cohorts), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events, Number of Participants with Adverse Events of Special Interest and 1 more. Started Feb 2024; status: completed.
02
Drugs
mRNA-0184
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06243770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06243770.